-New study published in Science Translational Medicine demonstrates microRNA-21 contributes to fibrogenesis in the kidney
-Regulus, in partnership with Sanofi, developing novel anti-fibrotic therapies targeting microRNAs
B.N. Chau et al.
“MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways”
Sci Transl Med 15 February 2012:
Vol. 4, Issue 121, p. 121ra18
Sci. Transl. Med. DOI: 10.1126/scitranslmed.3003205
http://stm.sciencemag.org/content/4/121/121ra18
LA JOLLA, Calif., Feb. 16, 2012 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that new preclinical data investigating the role of microRNA-21 (miR-21) in the treatment of kidney fibrosis has been published in the journal Science Translational Medicine. Regulus’ lead program for fibrosis targets miR-21, which is up-regulated in fibrotic tissues of humans. Previous preclinical studies by Regulus scientists and collaborators have shown that therapeutic oligonucleotides targeting miR-21 (anti-miR-21) can decrease fibrosis in preclinical models by reducing the expression of extracellular matrix proteins. Despite the current burden of fibrosis-related human disease, there are few therapies that can specifically treat this devastating disease.
“We are pleased with the published results demonstrating that targeting miR-21 with proprietary anti-miR oligonucleotides is effective at preventing kidney fibrosis in preclinical models,” said Neil W. Gibson, Ph.D., Regulus’ Chief Scientific Officer. ”We plan to select an anti-miR-21 development candidate [click to continue…]
Incoming search terms for this article:
-Regulus, Accelerate Brain Cancer Cure (ABC2) and Samsung Medical Center to Advance microRNA Therapeutics for Glioblastoma -
LA JOLLA, Calif., Dec. 12, 2011 /PRNewswire/ – Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the initiation of a new discovery effort in microRNA therapeutics for the treatment of glioblastoma multiforme (GBM), the most common and aggressive brain tumor in humans. Regulus will apply its expertise in microRNA therapeutics to discover chemically modified oligonucleotide anti-miRs for testing at the Samsung Medical Center in preclinical models that mimic human brain cancer. Accelerate Brain Cancer Cure (ABC2), a non-profit organization dedicated to accelerating therapies for brain cancer patients, has awarded Regulus a grant to support the research.
“GBM is a devastating disease with limited treatment options,” said Neil W. Gibson, Ph.D. Chief Scientific Officer of Regulus Therapeutics. “At Regulus, we have successfully targeted microRNAs in multiple disease settings and believe that targeting dysregulated microRNAs using [click to continue…]
Incoming search terms for this article:
-Regulus Scientists to Provide Update on Lead Therapeutic Program at American Society of Nephrology Meeting-
LA JOLLA, Calif., Nov. 8, 2011 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced presentations on its preclinical programs for the treatment of fibrosis at the American Association of Nephrology “Kidney Week” Annual Meeting held Nov. 8–13, 2011, in Philadelphia. New data will be presented demonstrating that microRNA-21 (miR-21) is upregulated in human patients and animal models with kidney injury and fibrosis. In preclinical models, genetic deletion of miR-21 or pharmacologic inhibition using proprietary anti-miR oligonucleotides decreased fibrotic gene expression and improved kidney fibrosis. These new data demonstrate that miR-21 contributes to fibrosis and epithelial injury in the kidney, and supports the development of anti-miR-21 oligonucleotides as a therapeutic approach for treating chronic kidney disease.
“In collaboration with Dr. Jeremy S. Duffield, M.D., Ph.D., University of Washington, we have shown that inhibition of miR-21 with our proprietary anti-miR oligonucleotides is effective at preventing [click to continue…]
Incoming search terms for this article:
- New publication in Nature shows therapeutic silencing of microRNA-33a/b for atherosclerosis:
Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides
K.J. Rayner et al.
Nature 478, 404–407 (20 October 2011)
http://www.nature.com/nature/journal/v478/n7369/full/nature10486.html
- Regulus Therapeutics and Collaborators Publish New Pre-Clinical Data on microRNA-33 Demonstrating Key Role in Cholesterol Homeostasis and Fatty Acid Metabolism
- Company to host webinar on October 26, 2011 to discuss findings
LA JOLLA, Calif., Oct. 20, 2011 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, and collaborators at NYU Langone Medical Center and Wake Forest Baptist Medical Center today announced the publication of new pre-clinical research findings in the journal Nature (Rayner et al., Nature, October 20, 2011). The new data show the first demonstration of marked increases in high density lipoprotein cholesterol (HDL-C), the ‘good’ cholesterol, and suppression of plasma triglyceride levels in non-human primates through inhibition of both microRNA-33a and microRNA-33b (miR-33a/b) with proprietary chemically modified anti-miR oligonucleotides. A webinar to discuss the new data will be hosted by Regulus and features Kathryn Moore, Ph.D., associate professor in the Department of Medicine at NYU Langone Medical Center and Regulus scientists (11:00am EDT, October 26, 2011).
“In addition to atherosclerotic plaque regression and enhanced reverse cholesterol transport that we previously observed in rodents with our collaborators at NYU Langone Medical Center, anti-miR-33 treatment is now shown to [click to continue…]
Incoming search terms for this article:
- Work of scientists with Regulus, Alnylam and ETH Zurich shows microRNAs 103/107 are upregulated in mouse models of obesity; targeting with anti-miRs improves glucose homeostasis and insulin sensitivity -
LA JOLLA, Calif., and CAMBRIDGE, Mass., June 8, 2011 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced the publication in Nature of new pre-clinical data in mice about the antagonism of microRNA-103 and microRNA-107 (miR-103/107). Data from a collaborative study performed by Regulus, Alnylam and ETH Zurich demonstrated that antagonism of miR-103/107 with proprietary chemically modified anti-miR oligonucleotides could promote insulin signaling in both liver and adipose tissue. Silencing miR-103/107 in animal models of obesity improved glucose homeostasis, suggesting that these microRNAs are potential targets for the treatment of diabetes.
Defects in insulin signaling are among the most common and earliest defects that predispose an individual to the development of type 2 diabetes. The new findings demonstrated that miR-103/107 are upregulated in obese mice, and silencing with anti-miRs could improve glucose homeostasis and insulin sensitivity, while gain of function in liver or fat caused impaired glucose homeostasis. Direct targets of miR-103/107 identified include [click to continue…]
Incoming search terms for this article:
Loading ...
